RADICAL RADIOTHERAPY FOR LOCALIZED ADENOCARCINOMA OF THE PROSTATE - A REPORT OF 191 CASES

被引:8
作者
ELGALLEY, RES
HOWARD, GCW
HAWKYARD, S
KLYS, H
KERR, GR
DUNCAN, W
CHISHOLM, GD
FOWLER, JW
机构
[1] WESTERN GEN HOSP,DEPT CLIN ONCOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND
[2] WESTERN GEN HOSP,DEPT UROL,EDINBURGH,MIDLOTHIAN,SCOTLAND
[3] WESTERN GEN HOSP,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND
来源
BRITISH JOURNAL OF UROLOGY | 1995年 / 75卷 / 01期
关键词
PROSTATE; CANCER; RADIOTHERAPY;
D O I
10.1111/j.1464-410X.1995.tb07229.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the results of radiotherapy in the treatment of localized prostate cancer. End points for assessment were survival, local control, development of metastases, and the toxicity of therapy. Materials and methods The case notes of 191 patients who were treated with radical radiotherapy between 1982 and 1992 were reviewed. The pathology of 130 patients was reviewed by a single pathologist. A multivariate analysis was performed to identify significant prognostic factors with regard to survival and relapse. Results One-hundred and eighty-two patients were assessable. The minimum length of follow-up was one year (median=40 months). The actuarial cause-specific 5 and 10 year survival rates were 63% and 35% respectively. Local progression occurred in 41% of patients with 37% developing metastases. Multivariate statistical analysis demonstrated that T stage and Gleason Score were significant predictors for survival. Late complications were usually mild, with only 4% developing serious bladder toxicity. Conclusion Radical radiotherapy has a role in the curative treatment of prostate cancer. Survival is significantly related to T stage at the time of presentation, and to the Gleason Score of the tumour. Survival in this series was not as good as the best surgical series, but it is still not clear which patients should receive radiotherapy and which surgery as their primary management.
引用
收藏
页码:38 / 43
页数:6
相关论文
共 15 条
[1]  
Bagshaw M A, 1988, NCI Monogr, P47
[2]  
BAYER D, 1981, UROLOGY S, V17, P7
[3]   PROSTATE-CANCER SCREENING - ACCEPTING THE CONSEQUENCES OF PSA TESTING [J].
CHISHOLM, GD .
BRITISH JOURNAL OF UROLOGY, 1993, 71 (04) :375-377
[4]   OPERABLE PROSTATIC-CARCINOMA - CORRELATIONS AMONG CLINICAL STAGE, PATHOLOGICAL STAGE, GLEASON HISTOLOGICAL SCORE AND EARLY DISEASE-FREE SURVIVAL [J].
FOWLER, JE ;
MILLS, SE .
JOURNAL OF UROLOGY, 1985, 133 (01) :49-52
[5]   TOTAL PROSTATECTOMY FOR LOCALIZED PROSTATIC-CANCER [J].
GIBBONS, RP ;
CORREA, RJ ;
BRANNEN, GE ;
MASON, JT .
JOURNAL OF UROLOGY, 1984, 131 (01) :73-76
[6]  
Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171
[7]   MEASURES OF MORTALITY IN PROSTATIC-CANCER [J].
GOODMAN, CM ;
RITCHIE, AWS ;
CHISHOLM, GD .
BRITISH JOURNAL OF CANCER, 1990, 61 (03) :465-468
[8]   RADICAL PROSTATECTOMY VERSUS EXPECTANT PRIMARY-TREATMENT IN STAGE-I AND STAGE-II PROSTATIC-CANCER - A 15-YEAR FOLLOW-UP [J].
GRAVERSEN, PH ;
NIELSEN, KT ;
GASSER, TC ;
CORLE, DK ;
MADSEN, PO .
UROLOGY, 1990, 36 (06) :493-498
[9]   ULTRASOUND GUIDED TRANS-RECTAL CORE BIOPSIES OF THE PALPABLY ABNORMAL PROSTATE [J].
HODGE, KK ;
MCNEAL, JE ;
STAMEY, TA .
JOURNAL OF UROLOGY, 1989, 142 (01) :66-70
[10]   ABILITY OF PREOPERATIVE SERUM PROSTATE-SPECIFIC ANTIGEN VALUE TO PREDICT PATHOLOGICAL STAGE AND DNA PLOIDY - INFLUENCE OF CLINICAL STAGE AND TUMOR GRADE [J].
KLEER, E ;
LARSONKELLER, JJ ;
ZINCKE, H ;
OESTERLING, JE .
UROLOGY, 1993, 41 (03) :207-216